This article only represents the author's own views.
Shenzhen Edge Medical Co. Ltd. hopes the second try will be the charm for its bid to list in Hong Kong, this time armed with a major new product approval. Eight months after its first IPO attempt, the surgical robot maker filed an updated prospectus last week revealing the regulatory nod for a key product that will bring the young company its first sales.
Compared with traditional techniques, surgical robots have clearer imaging systems and flexible robotic arms, and can carry out complex surgeries with minimal invasiveness. Such robots are increasingly popular for performing laparoscopic, orthopedic, neurological and percutaneous coronary intervention surgeries.
您已閱讀10%（722字），剩余90%（6271字）包含更多重要信息，訂閱以繼續探索完整內容，并享受更多專屬服務。